133 related articles for article (PubMed ID: 20228125)
1. Increased intratumoral androgens in human breast carcinoma following aromatase inhibitor exemestane treatment.
Takagi K; Miki Y; Nagasaki S; Hirakawa H; Onodera Y; Akahira J; Ishida T; Watanabe M; Kimijima I; Hayashi S; Sasano H; Suzuki T
Endocr Relat Cancer; 2010 Jun; 17(2):415-30. PubMed ID: 20228125
[TBL] [Abstract][Full Text] [Related]
2. 5Alpha-reductase type 1 and aromatase in breast carcinoma as regulators of in situ androgen production.
Suzuki T; Miki Y; Moriya T; Akahira J; Ishida T; Hirakawa H; Yamaguchi Y; Hayashi S; Sasano H
Int J Cancer; 2007 Jan; 120(2):285-91. PubMed ID: 17066438
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast.
Shibuya R; Suzuki T; Miki Y; Yoshida K; Moriya T; Ono K; Akahira J; Ishida T; Hirakawa H; Evans DB; Sasano H
Endocr Relat Cancer; 2008 Mar; 15(1):113-24. PubMed ID: 18310280
[TBL] [Abstract][Full Text] [Related]
4. Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients.
Chanplakorn N; Chanplakorn P; Suzuki T; Ono K; Chan MS; Miki Y; Saji S; Ueno T; Toi M; Sasano H
Breast Cancer Res Treat; 2010 Apr; 120(3):639-48. PubMed ID: 20151319
[TBL] [Abstract][Full Text] [Related]
5. Increased 5α-reductase type 2 expression in human breast carcinoma following aromatase inhibitor therapy: the correlation with decreased tumor cell proliferation.
Chanplakorn N; Chanplakorn P; Suzuki T; Ono K; Wang L; Chan MS; Wing L; Yiu CC; Chow LW; Sasano H
Horm Cancer; 2011 Feb; 2(1):73-81. PubMed ID: 21761341
[TBL] [Abstract][Full Text] [Related]
6. Intracrinology of estrogens and androgens in breast carcinoma.
Sasano H; Suzuki T; Miki Y; Moriya T
J Steroid Biochem Mol Biol; 2008 Feb; 108(3-5):181-5. PubMed ID: 17933521
[TBL] [Abstract][Full Text] [Related]
7. Androgens in human breast carcinoma.
Suzuki T; Miki Y; Takagi K; Hirakawa H; Moriya T; Ohuchi N; Sasano H
Med Mol Morphol; 2010 Jun; 43(2):75-81. PubMed ID: 20683693
[TBL] [Abstract][Full Text] [Related]
8. Aromatase localization in human breast cancer tissues: possible interactions between intratumoral stromal and parenchymal cells.
Miki Y; Suzuki T; Tazawa C; Yamaguchi Y; Kitada K; Honma S; Moriya T; Hirakawa H; Evans DB; Hayashi S; Ohuchi N; Sasano H
Cancer Res; 2007 Apr; 67(8):3945-54. PubMed ID: 17440110
[TBL] [Abstract][Full Text] [Related]
9. Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial.
Bundred NJ; Cramer A; Morris J; Renshaw L; Cheung KL; Flint P; Johnson R; Young O; Landberg G; Grassby S; Turner L; Baildam A; Barr L; Dixon JM
Clin Cancer Res; 2010 Mar; 16(5):1605-12. PubMed ID: 20179229
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral localization and activity of 17β-hydroxysteroid dehydrogenase type 1 in non-small cell lung cancer: a potent prognostic factor.
Verma MK; Miki Y; Abe K; Suzuki T; Niikawa H; Suzuki S; Kondo T; Sasano H
J Transl Med; 2013 Jul; 11():167. PubMed ID: 23837683
[TBL] [Abstract][Full Text] [Related]
11. Effects of aromatase inhibitors on human osteoblast and osteoblast-like cells: a possible androgenic bone protective effects induced by exemestane.
Miki Y; Suzuki T; Hatori M; Igarashi K; Aisaki KI; Kanno J; Nakamura Y; Uzuki M; Sawai T; Sasano H
Bone; 2007 Apr; 40(4):876-87. PubMed ID: 17254854
[TBL] [Abstract][Full Text] [Related]
12. In situ androgen and estrogen biosynthesis in endometrial cancer: focus on androgen actions and intratumoral production.
Ito K; Miki Y; Suzuki T; McNamara KM; Sasano H
Endocr Relat Cancer; 2016 Jul; 23(7):R323-35. PubMed ID: 27287451
[TBL] [Abstract][Full Text] [Related]
13. Androgen metabolite-dependent growth of hormone receptor-positive breast cancer as a possible aromatase inhibitor-resistance mechanism.
Hanamura T; Niwa T; Nishikawa S; Konno H; Gohno T; Tazawa C; Kobayashi Y; Kurosumi M; Takei H; Yamaguchi Y; Ito K; Hayashi S
Breast Cancer Res Treat; 2013 Jun; 139(3):731-40. PubMed ID: 23780684
[TBL] [Abstract][Full Text] [Related]
14. Intracrinology of sex steroids in ductal carcinoma in situ (DCIS) of human breast: comparison to invasive ductal carcinoma (IDC) and non-neoplastic breast.
Miki Y; Suzuki T; Sasano H
J Steroid Biochem Mol Biol; 2009 Mar; 114(1-2):68-71. PubMed ID: 19444935
[TBL] [Abstract][Full Text] [Related]
15. Androgens inhibit the stimulatory action of 17β-estradiol on normal human breast tissue in explant cultures.
Eigeliene N; Elo T; Linhala M; Hurme S; Erkkola R; Härkönen P
J Clin Endocrinol Metab; 2012 Jul; 97(7):E1116-27. PubMed ID: 22535971
[TBL] [Abstract][Full Text] [Related]
16. Aromatase inhibitor exemestane has antiproliferative effects on human mesothelioma cells.
Stoppoloni D; Salvatori L; Biroccio A; D'Angelo C; Muti P; Verdina A; Sacchi A; Vincenzi B; Baldi A; Galati R
J Thorac Oncol; 2011 Mar; 6(3):583-91. PubMed ID: 21289517
[TBL] [Abstract][Full Text] [Related]
17. The androgen metabolite 5alpha-androstane-3beta,17beta-diol (3betaAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance.
Sikora MJ; Cordero KE; Larios JM; Johnson MD; Lippman ME; Rae JM
Breast Cancer Res Treat; 2009 May; 115(2):289-96. PubMed ID: 18521740
[TBL] [Abstract][Full Text] [Related]
18. Sex steroid-producing enzymes in human breast cancer.
Suzuki T; Miki Y; Nakamura Y; Moriya T; Ito K; Ohuchi N; Sasano H
Endocr Relat Cancer; 2005 Dec; 12(4):701-20. PubMed ID: 16322318
[TBL] [Abstract][Full Text] [Related]
19. [Anastrozole-resistant breast cancer responsive to exemestane--a case report].
Sakurai T; Oura S; Hirai I; Tanino H; Yoshimas T; Kokawa Y; Nishida M; Sasaki R; Kinoshita T; Bessho T; Yokochi H; Nishimura O; Okamura Y
Gan To Kagaku Ryoho; 2004 Nov; 31(12):2051-3. PubMed ID: 15570939
[TBL] [Abstract][Full Text] [Related]
20. 5alpha-reductases in human breast carcinoma: possible modulator of in situ androgenic actions.
Suzuki T; Darnel AD; Akahira JI; Ariga N; Ogawa S; Kaneko C; Takeyama J; Moriya T; Sasano H
J Clin Endocrinol Metab; 2001 May; 86(5):2250-7. PubMed ID: 11344235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
